Guggenheim raised the firm’s price target on Twist Bioscience (TWST) to $55 from $50 and keeps a Buy rating on the shares. The firm adjusted models and forecasts for select companies in its diagnostics and life science tools coverage to reflect recent updates from the companies after meetings with management teams.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TWST:
- Cathie Wood Pours $16M into Circle Stock, Dumps ROKU, TSM, TWST, BLSH
- Twist Bioscience Stock (TWST) Tumbles after Senior Executive Offloads $2M in Shares
- Cathie Wood Loads Up on Biotech Stocks While Trimming Several Tech Positions
- Cathie Wood Pours Millions into Broadcom, AMD, Coinbase – Sells $13M Teradyne
- Twist Bioscience: Invenra Licensing Deal Strengthens AI-Driven Bispecific Antibody Platform and Supports Outperform Rating